Draft Guidance: Early Drug Development and the Role of Pre-IND Meetings

The FDA has released a new draft guidance for sponsors of drug and biological products for the
treatment of rare diseases in early development and in the planning of and participation in formal
pre-investigational new drug application (pre-IND) meetingsRead the full guidance here or click the image to download.

Author Details

Paul Mirek
Phone Us Now
Email Us Now